Contribution: Industrial Research Assistance Program – Contributions to Firms
iProgen Biotech Inc.
$198,141.00
Production and Evaluation of Multiple ADED-Enhanced ADCs
FY 2018-19 · 2018-09-01
Summary
This project will enable iProgen Biotech to produce and evaluate a number of different antibody-drug conjugates (ADCs) that are performance-enhanced by the firm's proprietary technology. The results of this project will allow the firm to identify a lead therapeutic drug candidate to take through IND-enabling preclinical development .
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Burnaby|Burnaby, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
826908816
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-09-01 | 2018-19 | $188,141.00 |
| 1 | 2018-09-01 | 2018-19 | $198,141.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 10,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 10 000 dollars.
Agreement End Date
2019-08-31
Agreement Number
912889
Agreement Start Date
2018-09-01
Agreement Title
Production and Evaluation of Multiple ADED-Enhanced ADCs
Agreement Title (French)
Production et évaluation de multiples CAM améliorés par ADED
Agreement Type
Contribution
Agreement Value
$198,141.00
Amendment Date
2019-03-29
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project will enable iProgen Biotech to produce and evaluate a number of different antibody-drug conjugates (ADCs) that are performance-enhanced by the firm's proprietary technology. The results of this project will allow the firm to identify a lead therapeutic drug candidate to take through IND-enabling preclinical development .
Description (French)
Ce projet permettra à iProgen Biotech de produire et d’évaluer un certain nombre de conjugués anticorps-médicaments (CAM) améliorés par la technologie exclusive de l'entreprise. Les résultats de ce projet permettront à l’entreprise d’identifier un médicament candidat phare susceptible de faire l’objet d’un développement de nouveau médicament de recherche (NMR) préclinique favorable.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Burnaby North--Seymour
Federal Riding (French)
Burnaby-Nord--Seymour
Federal Riding Number
59002
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
826908816
Recipient City
Burnaby|Burnaby
Recipient Country
CA
Recipient Legal Name
iProgen Biotech Inc.
Recipient Postal Code
V5A 4N4
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2018-2019-Q2-912889
